NCT00728936 - Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

May 31, 2010

Conditions

Hepatitis C

Interventions

DRUG

IMO-2125

IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system

DRUG

Saline placebo

saline placebo given subcutaneously

Trial Locations (7)

27705

Duke University Medical Center, Durham

30060

Gastoenterstinal Specialist of Georgia, PA, Marietta

48377

Henry Ford Med Ctr- Columbus, Novi

75203

The Liver Institute, Dallas

78215

Alamo Medical Research, San Antonio

80045

University of Colorado Hospital, Aurora

00909

Fundacion de Investigacion de Diego, Santurce